Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 2/20 | 0.52 |
| ▸ | CTSL | P07711 | 2/20 | 0.52 |
| ▸ | RARB | P10826 | 10/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.50 |
| ▸ | RARA | P10276 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MTOR | P42345 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | MPL | P40238 | 2/20 | 0.47 |
| ▸ | RARG | P13631 | 1/20 | 0.44 |
| ▸ | BRS3 | P32247 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6151728 | 0.95 | RARB (0.54) | CTSVCTSLRARBMEN1KMT2A | |
| SCHEMBL6152182 | 0.95 | MPL (0.52) | CTSVCTSLRARBMEN1KMT2A | |
| SCHEMBL6153025 | 0.87 | RARB (0.47) | CTSVCTSLRARBMEN1KMT2A | |
| SCHEMBL6152138 | 0.86 | TSHR (0.55) | CTSVCTSLRARBMEN1KMT2A | |
| SCHEMBL6152142 | 0.85 | CTSV (0.49) | CTSVCTSLRARBMEN1KMT2A | |
| SCHEMBL6152951 | 0.83 | CNR2 (0.52) | CTSVCTSLGPR84 | |
| SCHEMBL6152019 | 0.83 | RARB (0.50) | CTSVCTSLRARBGPR84 | |
| SCHEMBL23014696 | 0.77 | RARB (0.66) | RARBMEN1KMT2ARARAALDH1A1 | |
| SCHEMBL1534366 | 0.77 | RARB (0.66) | RARBMEN1KMT2ARARAALDH1A1 | |
| SCHEMBL11239422 | 0.77 | RARB (0.66) | RARBMEN1KMT2ARARAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1253151-B1 | Pyrromethene metal complex and light emitting device composition and light emitting devices using the same | TORAY INDUSTRIES (JP) | 2005-01-12 | — | — | EP | disclosed |
| US-6805978-B2 | COMPLEX CONTAINING DIKETOPYRROLO(3,4-C)PYRROLE COMPOUND | TORAY INDUSTRIES, INC. (JP) | 2004-10-19 | — | — | US | disclosed |
| US-20030082406-A1 | Complex containing diketopyrrolo(3,4-c)pyrrole compound | TORAY INDUSTRIES, INC. (JP) | 2003-05-01 | — | — | US | disclosed |
| EP-1253151-A1 | Pyrromethene metal complex and light emitting device composition and light emitting devices using the same | TORAY INDUSTRIES, INC. (JP) | 2002-10-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030082406-A1 | Complex containing diketopyrrolo(3,4-c)pyrrole compound | PPOX, CPNE4, TP53RK | CTSV 2058/4885CTSL 2295/4885RARB 2079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.